A Phase 1 Open-Label Multicenter Study to Assess Safety Tolerability PK and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Solid Tumor
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. A participant has a measurable disease by RECIST 1.1 criteria as assessed by investigator. 2. Has ECOG performance status of 0 or 1 within 7 days before first dose of study intervention. 3. Has the ability to swallow and retain oral medication. 4. A female participant is eligible to participate if she is not pregnant or breastfeeding. 5. Male participants must agree to use contraception unless confirmed to be azoospermic.

You may not be eligible for this study if the following are true:

  • 1. Received chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2 weeks for palliative radiation) before first dose of study intervention or has not recovered to NCI-CTCAE, version 5.0 Grade 1 or better. 2. History of a second malignancy (ie, a malignancy of a type other than the one currently under treatment), unless potentially curative treatment has been completed with no evidence of malignancy for 5 years. 3. Clinically active CNS metastases and/or carcinomatous meningitis. Participants with treated brain or meningeal metastases may participate if lesions are radiologically stable. 4. Known hypersensitivity to MK-1084 and/or pembrolizumab or any of its excipients. 5. Active infection requiring systemic therapy. 6. History of HIV and/or hepatitis B or C infections.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.